Clinical Trial Detail

NCT ID NCT04143711
Title Study of DF1001 in Patients With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Dragonfly Therapeutics

urethra transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

Advanced Solid Tumor

breast cancer



DF1001 + Pembrolizumab

Age Groups: senior adult

Additional content available in CKB BOOST